Back to Resources

Enhertu Focuses on Development and Approvals in Q2 2026

Market Highlights

  • AstraZeneca and Daiichi Sankyo announced development efforts, data presentations, and approval status updates across breast cancer and solid tumor indications for Enhertu. A new AI assistant was also introduced.

Questions about this SnapShot or other markets?

U.S. MARKETS

Christine Alongi
alongi@dtwresearch.com

GLOBAL MARKETS

Robin Cefalo
cefalo@dtwresearch.com

SOCIAL MEDIA MARKETS

Andrew Carney
carney@dtwresearch.com

Get in Touch

Want to see what we can do for your organization? We’ll walk you through CDP, train your team, and stay close with ongoing support.

Contact us